Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors
- Levine, A. Joan
- Phipps, Amanda I.
- Baron, John A.
- Buchanan, Daniel D.
- Ahnen, Dennis J.
- Cohen, Stacey A.
- Lindor, Noralane M.
- Newcomb, Polly A.
- Rosty, Christophe
- Haile, Robert W.
- Laird, Peter W.
- Weisenberger, Daniel J.
DOIAbstract
The CpG Island Methylator Phenotype (CIMP) is a major molecular pathway in colorectal cancer (CRC). Approximately 25% to 60% of CIMP tumors are microsatellite unstable (MSI-H) due to DNA hypermethylation of the MLH1 gene promoter. Our aim was to determine if the distributions of clinicopathologic factors in CIMP-positive tumors with MLH1 DNA methylation differed from those in CIMP-positive tumors without DNA methylation of MLH1
Add to ORKG